Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin

NCT ID: NCT00411190

Last Updated: 2017-10-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-10-19
• Study Completion Date: 2006-12-15

Brief Summary

Relacatib is being developed for the treatment of osteoporosis, osteoarthritis and possibly other bone disorders. Recent results suggest that relacatib interacts with the way our bodies metabolise drugs and so some drugs which are commonly prescribed to the intended target patient population could be affected by giving relacatib at the same time. The purpose of this study is to evaluate the effect of repeat dose administration of relacatib on the way subjects bodies metabolise three commonly prescribed medications in the osteoarthritis population: ibuprofen, acetaminophen, and atorvastatin.

Conditions

Osteoarthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Session 1

Subjects will receive 500 mg acetaminophen on Day 1, 400 mg ibuprofen on Day 2, 40 mg atorvastatin on Day 3.

Group Type: EXPERIMENTAL

Acetaminophen

Intervention Type: DRUG

Acetaminophen will be administered orally

Ibuprofen

Intervention Type: DRUG

Ibuprofen will be administered orally

Atorvastatin

Intervention Type: DRUG

Atorvastatin will be administered orally

Session 2

Subjects will be randomized to receive relacatib 60 mg or 120 mg from Day 1-14. On Day 15 subjects will receive 500 mg acetaminophen, 400 mg ibuprofen on Day 16 and 40 mg atorvastatin on Day 17 with usual dose of relacatib.

Group Type: EXPERIMENTAL

Relacatib

Intervention Type: DRUG

Subjects will administer 60 or 120 mg tablets in Session 2

Acetaminophen

Intervention Type: DRUG

Acetaminophen will be administered orally

Ibuprofen

Intervention Type: DRUG

Ibuprofen will be administered orally

Atorvastatin

Intervention Type: DRUG

Atorvastatin will be administered orally

Interventions

Relacatib

Subjects will administer 60 or 120 mg tablets in Session 2

Intervention Type: DRUG

Acetaminophen

Acetaminophen will be administered orally

Intervention Type: DRUG

Ibuprofen

Ibuprofen will be administered orally

Intervention Type: DRUG

Atorvastatin

Atorvastatin will be administered orally

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy
• Postmenopausal
• Body weight > 50 kg
• Body mass index (BMI) between 19 and 30
• The subject is willing and able to give a signed and dated written informed consent prior to admission to the study
• The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.

Exclusion Criteria

• Subjects with known morphea or sclerodermia
• Subjects with a history of myocardial infarction.
• Subjects with a history of renal/or hepatic disease unless the disease has been successfully treated and is no longer active; subjects with any evidence of renal/ or hepatic impairment on the screening physical and laboratory examination.
• Subjects with history of hypertension or systolic blood pressure
• Subjects with history of diabetes
• History of regular alcohol consumption exceeding 7 drinks/week (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening.
• History of use of tobacco- or nicotine-containing products within 6 months of screening, or a positive urine cotinine indicative of smoking at screening.
• Positive urine drug screen including alcohol (or alcohol breath test) at screening.
• Positive for HIV, hepatitis B virus or hepatitis C virus.
• Donation of blood in excess of 500 mL within 56 days prior to dosing
• History of sensitivity or contraindications to any of the study medications (i.e., relacatib, paracetamol, ibuprofen or atorvastatin) or components thereof.
• Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
• Subjects whom are judged by the investigator to be at risk for acute angle closure glaucoma.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Antwerp, , Belgium

GSK Investigational Site

Liège, , Belgium

Countries

Belgium

Other Identifiers

SB-462795/008

Identifier Type: -

Identifier Source: org_study_id